Mazindol ER is under clinical development by NLS Pharmaceutics and currently in Phase II for Type 1 Narcolepsy (Narcolepsy with Cataplexy). According to GlobalData, Phase II drugs for Type 1 Narcolepsy (Narcolepsy with Cataplexy) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mazindol ER LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mazindol ER overview
Mazindol ER is under development for the treatment of narcolepsy type 1 and Idiopathic hypersomnia (IH). The drug candidate is a small molecule which is administered through oral route. It was also under development for attention deficit hyperactivity disorder (ADHD) and restless legs syndrome (RLS). The drug candidate acts by targeting dopamine and norepinephrine reuptake and OX2R.
NLS Pharmaceutics overview
NLS Pharmaceutics (NLS Pharma) is a drug development company that focuses on a strong scientific understanding of neurobehavioral and neurocognitive disorders and their pharmacognosy. NLS Pharma is headquartered in Stans, Switzerland.
For a complete picture of Mazindol ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
